美杰赛尔

Shenzhen Meijie Saier Biotechnology is a clinical-stage biopharmaceutical company based in Shenzhen, China, dedicated to the development of advanced cell therapies for cancer. The company specializes in chimeric antigen receptor (CAR) technologies, including autologous and universal CAR-T cells, as well as CAR-NK cell therapies. Its lead candidate, MJ-001, is a CD19-targeted CAR-T therapy currently in clinical trials for B-cell non-Hodgkin lymphoma. Beyond hematological malignancies, Meijie Saier is actively developing treatments for solid tumors, targeting antigens such as mesothelin and glypican-3. The company maintains integrated R&D and GMP manufacturing capabilities to support its diverse pipeline. Through its innovative platforms, Meijie Saier aims to improve the efficacy and accessibility of immunotherapy for patients worldwide.